DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Evan S. Dellon  1     Marc E. Rothenberg  2     Albert J. Bredenoord  3     Qiong Zhao  4     Urvi Mujumdar  5     Siddhesh Kamat  5     Bolanle Akinlade  5     Elizabeth Laws  6     Nikhil Amin  6     Paul J. Rowe  6     Yamo Deniz  6     Juby A. Jacob-Nara  6     Kiran Patel  6     Veronica Mas Casullo  6     Leda Mannent  7     Jonathan Spergel  8    
1 University of North Carolina School of Medicine, Chapel Hill, United States
2 Cincinnati Children's Hospital and University of Cincinnati College of Medicine, Cincinnati, United States
3 Amsterdam University Medical Center, Amsterdam, Netherlands
4 Regeneron Pharmaceuticals, Inc, Tarrytown, United States
5 Sanofi, Cambridge, United States
6 Sanofi, Bridgewater, United States
7 Sanofi, Chilly-Mazarin, France
8 Children's Hospital of Philadelphia, Philadelphia, United States

Topic
IBD

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing